Director Stephen Klasko Receives 100,000 RSUs at DocGo (DCGO)

Rhea-AI Filing Summary

Stephen K. Klasko, a director of DocGo Inc. (DCGO), was granted 100,000 restricted stock units (RSUs) under the Issuer's 2021 Stock Incentive Plan. Each RSU represents the right to receive one share of DocGo common stock upon vesting.

The RSUs vest on September 10, 2026 subject to the terms of the plan. The reported grant carried a $0 per-share price and, after the grant, Mr. Klasko is reported to beneficially own 115,000 shares. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.

Positive

• 100,000 RSUs granted to Director Stephen K. Klasko under the 2021 Stock Incentive Plan
• Each RSU equals one share upon vesting, providing clear conversion terms
• Vesting date specified (September 10, 2026), giving transparency on timing
• Beneficial ownership disclosed: reporting shows 115,000 shares following the grant

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A routine director equity grant was reported; it increases the director's stake and ties compensation to future service or performance.

The Form 4 documents a non-cash grant of 100,000 RSUs to Director Stephen K. Klasko under the companys 2021 Stock Incentive Plan. Each RSU converts to one share upon vesting, which is scheduled for September 10, 2026. The disclosure shows beneficial ownership rising to 115,000 shares. This is a standard equity-based compensation disclosure for an insider and does not by itself indicate a change in corporate control or an unusual governance event.

Compensation Analyst

TL;DR: The grant is a standard long-term equity award structure that vests over time; impact is routine unless tied to additional undisclosed conditions.

The reported award consists of 100,000 RSUs granted at a reported price of $0, with vesting on September 10, 2026 and an exchange ratio of one RSU per share. Such awards are commonly used to align director incentives with shareholder value over multiple years. The filing lists the post-transaction beneficial ownership as 115,000 shares, reflecting the directors current stake plus the newly reported RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klasko Stephen K. M.D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,000	$0.00	--

Holdings After Transaction: Common Stock — 115,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klasko Stephen K. M.D.

(Last) (First) (Middle)

C/O DOCGO INC

35 WEST 35TH STREET, FLOOR 6

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DocGo Inc. [ DCGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		A		100,000(1)	A	$0	115,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2021 Stock Incentive Plan (the "Plan") that will vest on September 10, 2026, subject to the terms of the Plan. Each RSU represents the right to receive, upon vesting, one share of Common Stock, subject to the terms of the Plan.

	/s/ Ely D. Tendler, as Attorney-in-Fact for Stephen K. Klasko, MD	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.